ArticleProceedings of the National Academy of Sciences of the United States of America2009
The cytokine interleukin-33 mediates anaphylactic shock.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 285 citations in OpenAlex.
- GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: opposing roles for GATA2 and GATA1 in human IL1RL1/ST2 gene expression.The Journal of biological chemistry · 2012Trial
- Biological mechanisms and therapeutic prospects of interleukin-33 in pathogenesis and treatment of allergic disease.Journal of inflammation (London, England) · 2025Review
- Predictive value of low serum interleukin-33 levels in acute ischemic stroke outcomes.Frontiers in neurology · 2024Article
- Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions.Vaccines · 2023Article
- IL-33 induces histidine decarboxylase, especially in c-kitInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Mast Cell Cytokines in Acute and Chronic Gingival Tissue Inflammation: Role of IL-33 and IL-37.International journal of molecular sciences · 2022Review
- Serum levels and single nucleotide polymorphisms of the interleukin-33 gene in atopic dermatitis.Postepy dermatologii i alergologii · 2022Article
- β-Defensin 2, an Antimicrobial Peptide, as a Novel Biomarker for Ulcerative Interstitial Cystitis; Can β-Defensin 2 Suspect the Dysbiosis of Urine Microbiota?Diagnostics (Basel, Switzerland) · 2021Article
- Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema.Biology · 2021Article
- Pediococcus Pentosaceus from the Sweet Potato Fermented Ger-Minated Brown Rice Can Inhibit Type I Hypersensitivity in RBL-2H3 Cell and BALB/c Mice Models.Microorganisms · 2021Article
- Diversified Stimuli-Induced Inflammatory Pathways Cause Skin Pigmentation.International journal of molecular sciences · 2021Review
- Association Between Immunoglobulin E Levels and Kaposi Sarcoma in African Adults With Human Immunodeficiency Virus Infection.The Journal of infectious diseases · 2021Article
- Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33.Journal of inflammation research · 2021Article
- Canine atopic dermatitis: Role of luteolin as new natural treatment.Veterinary medicine and science · 2020Article
- Roles of inflammation factors in melanogenesis (Review).Molecular medicine reports · 2020Review
- Keratinocyte-specific deletion of SHARPIN induces atopic dermatitis-like inflammation in mice.PloS one · 2020Article
- IL-33 deficiency causes persistent inflammation and severe neurodegeneration in retinal detachment.Journal of neuroinflammation · 2019Article
- FcεRI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions.International journal of molecular sciences · 2019Review
- Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.The Journal of allergy and clinical immunology · 2019Review
- IL-33 in obesity: where do we go from here?Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Correction · 2012-09-18Concerns/Issues about Referencing/Attributions · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) · · Corrects references in retraction notice
- Retraction · 2012-08-13Duplication of/in Image · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Anaphylactic shock is characterized by elevated immunoglobulin-E (IgE) antibodies that signal via the high affinity Fc epsilon receptor (Fc epsilonRI) to release inflammatory mediators. Here we report that the novel cytokine interleukin-33 (IL-33) potently induces anaphylactic shock in mice and is associated with the symptom in humans. IL-33 is a new member of the IL-1 family and the ligand for the orphan receptor ST2. In humans, the levels of IL-33 are substantially elevated in the blood of atopic patients during anaphylactic shock, and in inflamed skin tissue of atopic dermatitis patients. In murine experimental atopic models, IL-33 induced antigen-independent passive cutaneous and systemic anaphylaxis, in a T cell-independent, mast cell-dependent manner. In vitro, IL-33 directly induced degranulation, strong eicosanoid and cytokine production in IgE-sensitized mast cells. The molecular mechanisms triggering these responses include the activation of phospholipase D1 and sphingosine kinase1 to mediate calcium mobilization, Nuclear factor-kappaB activation, cytokine and eicosanoid secretion, and degranulation. This report therefore reveals a hitherto unrecognized pathophysiological role of IL-33 and suggests that IL-33 may be a potential therapeutic target for anaphylaxis, a disease of considerable unmet medical need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.